Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial

被引：0
|
作者：
Eyerich, Kilian [1 ]
Gottlieb, Alice B. [2 ]
Piaserico, Stefano [3 ]
Beissert, Stefan [4 ]
Gooderham, Melinda [5 ,6 ]
Kirby, Brian [7 ]
Tilt, Nicola [8 ]
Madden, Cynthia [9 ]
Wiegratz, Susanne [10 ]
de Cuyper, Dirk [11 ]
Elewski, Boni [12 ]
机构：
[1] Univ Freiburg, Dept Dermatol, Med Ctr, Freiburg, Germany
[2] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
[3] Univ Padua, Dept Med, Dermatol Unit, Padua, Italy
[4] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany
[5] Prob Med Res, SKiN Ctr Dermatol, Peterborough, ON, Canada
[6] Queens Univ, Kingston, ON, Canada
[7] Univ Coll Dublin, St Vincents Univ Hosp, Elm Pk & Charles Inst, Dublin, Ireland
[8] UCB Pharma, Slough, Berks, England
[9] UCB Pharma, Morrisville, NC USA
[10] UCB Pharma, Monheim, Germany
[11] UCB Pharma, Brussels, Belgium
[12] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
43878
引用
收藏
页码：AB22 / AB22
页数：1
相关论文
共 50 条
  • [31] Effectiveness and safety of secukinumab in patients with moderate to severe plaque psoriasis
    Moron, R.
    Alvarez, R.
    Nieto, P.
    Garcia, C.
    Belda, S.
    Cabeza, J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 378 - 378
  • [32] Bimekizumab versus secukinumab in plaque psoriasis: Reduction in body surface area affected by psoriasis translates into benefits in patient-perceived itching, skin pain, and scaling and health-related quality of life in the BE RADIANT phase 3b trial
    Augustin, Matthias
    Gooderham, Melinda
    Gottlieb, Alice B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB25 - AB25
  • [33] Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
    Kokolakis, Georgios
    Warren, Richard B.
    Strober, Bruce
    Blauvelt, Andrew
    Puig, Luis
    Morita, Akimichi
    Gooderham, Melinda
    Koerber, Andreas
    Vanvoorden, Veerle
    Wang, Maggie
    de Cuyper, Dirk
    Madden, Cynthia
    Gomez, Natalie Nunez
    Lebwohl, Mark
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (03) : 330 - 340
  • [34] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
    Merola, Joseph
    Tatulych, Svitlana
    Kaur, Mandeep
    Lan, Shuping
    Mallbris, Lotus
    Mamolo, Carla
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S9 - S9
  • [35] Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
    Blauvelt, Andrew
    Armstrong, April W.
    Langley, Richard G.
    Gebauer, Kurt
    Thaci, Diamant
    Bagel, Jerry
    Guenther, Lyn C.
    Paul, Carle
    Randazzo, Bruce
    Flavin, Susan
    Hsu, Ming-Chun
    You, Yin
    Reich, Kristian
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2317 - 2324
  • [36] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
    Merola, Joseph
    Tatulych, Svitlana
    Mamolo, Carla
    Lan, Shuping
    Mallbris, Lotus
    Kaur, Mandeep
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
  • [37] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis
    Kaur, M.
    Merola, J.
    Tatulych, S.
    Mamolo, C.
    Lan, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 81 - 81
  • [38] Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials
    Gottlieb, A. B.
    Thaci, D.
    Leonardi, C.
    Poulin, Y.
    Kavanagh, S.
    Boehnlein, M.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 54 - 54
  • [39] BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS
    Merola, J. F.
    Gottlieb, A. B.
    Morita, A.
    Carrascosa, J. M.
    Elewski, B.
    Tilt, N.
    Wiegratz, S.
    Wixted, K.
    Mrowietz, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1766 - 1767
  • [40] Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial
    Reich, Kristian
    Merola, Joseph F.
    Elewski, Boni
    Papp, Kim A.
    Puig, Luis
    Rich, Pheobe
    Cioffi, Christopher
    Cullen, Eva
    Peterson, Luke
    Gottlieb, Alice B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB70 - AB70
12345